Our unique process, paired withinnovation and continued improvement and evolution, puts us at the forefront.
Humacyte Appoints Dr. Chris Fang as Chief Medical Officer
Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference
NC Companies Shine At SEBIO Forum
Humacyte Commences Phase II Vascular Trauma Trial
From lower costs to fewer operations, HAVs may offer critical benefits.
With each year, we’ve movedcloser to lifesaving treatments.